CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China ...

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) has achieved a major milestone in the fight against acute myeloid leukemia ...

The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to AbelZeta ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Autolus Therapeutics' autologous CD19-directed CAR T-cell therapy Aucatzyl ...

The Global Breast Reconstruction Market is expected to reach at a CAGR of 6.4% during the forecast period (2024-2031). The Breast Reconstruction Market is growing rapidly, driven by rising breast ...

Located at the system's hospital in St. George, Utah, the clinic intends to offer T-cell collection closer to home.

New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients ...

An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and progression-free for more than 5 years after a single CARVYKTI® ...

Results showed athletes who received osteochondral autologous transplantation successfully returned to sport. All patients also experienced pain relief. SAN DIEGO — Osteochondral autologous ...

Could you provide a simple explanation of CAR T-cell therapy, highlighting the key differences between autologous and allogeneic approaches? CAR T-cell therapy is really an exciting treatment for ...